Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8237562 | 0.88 | PIK3CG (0.44) | PIK3CGKCNH2ATMCYP11B2CYP11B1 | |
| Citric Acid SCHEMBL4330109 | 0.86 | PIK3CG (0.41) | PIK3CGCYP11B2CYP11B1CYP1A2MKNK1 | |
| Citric Acid SCHEMBL4327392 | 0.86 | PIK3CG (0.45) | PIK3CGCYP11B2CYP11B1CYP1A2 | |
| Citric Acid SCHEMBL4336984 | 0.83 | PIK3CG (0.47) | PIK3CGCYP11B1CYP1A2 | |
| Citric Acid SCHEMBL4323283 | 0.81 | PIK3CG (0.46) | PIK3CGCYP11B1CYP1A2 | |
| Citric Acid SCHEMBL4333388 | 0.80 | TSHR (0.43) | PIK3CGCYP11B2CYP11B1 | |
| Citric Acid SCHEMBL4327809 | 0.80 | PIK3CG (0.41) | PIK3CGCYP11B2CYP11B1CYP1A2MKNK1 | |
| Citric Acid SCHEMBL4339096 | 0.80 | TSHR (0.44) | PIK3CG | |
| SCHEMBL4324289 | 0.79 | PIK3CG (0.47) | PIK3CGCYP11B2CYP11B1CYP1A2MKNK1 | |
| SCHEMBL4976043 | 0.76 | PIK3CG (0.44) | PIK3CGCYP11B2CYP11B1CYP1A2CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149505-A1 | Metabotropic Glutamate Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | claimed |
| US-20090149505-A1 | Metabotropic Glutamate Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2009-06-11 | — | — | US | disclosed |
| EP-1986998-A1 | METABOTROPIC GLUTAMATE RECEPTOR-POTENTIATING SOINDOLONES | AstraZeneca AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007095024-A1 | METABOTROPIC GLUTAMATE RECEPTOR-POTENTIATING ΓSOINDOLONES | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149505-A1 | Metabotropic Glutamate Receptor-Potentiating Isoindolones | GRM1, GRIN1, GRM3 | PIK3CG 1976/4885KCNH2 323/4885ATM 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.